TTrialPathMatch Me to Trials
← Back to trials
RecruitingEndometrial Adenocarcinoma

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Eligible age

18+ yrs

Accepts

Women

Locations

31 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.

Sponsor: Acrivon Therapeutics

You may qualify if…

  • ✓ 1. Participant must be able to give signed, written informed consent.
  • ✓ 2. Participant must have histologically documented, high-grade endometrial cancer.
  • ✓ Arms 1 and 2
  • ✓ 1. All high-grade epithelial endometrial histological subtypes are eligible including: endometrioid (all Grade 3), serous, carcinosarcomas, clear-cell carcinoma, and mixed histologies.
  • ✓ Note: Subjects with p53 mutant Grade 2 endometrioid cancer are eligible
  • ✓ Arms 3 and 4
  • ✓ 2. Serous carcinoma or mixed tumors with a majority component of serous carcinoma or carcinosarcoma where the carcinomatous component is serous carcinoma.
  • ✓ 3. Treatment History Requirements:

You may not qualify if…

  • ✕ 1. Participant with known symptomatic brain metastases requiring \> 10 mg/day of prednisolone (or its equivalent). Participants with previously diagnosed brain metastases are eligible if they have completed their treatment, have recovered from the acute effects of radiation therapy or surgery prior to the start of ACR-368 treatment, fulfill the steroid requirement for these metastases, and are neurologically stable based on central nervous system imaging ≥ 4 weeks after treatment.
  • ✕ 2. Participant has mesenchymal tumors of the uterus.
  • ✕ 3. Participant has a history of clinically meaningful ascites, defined as history of paracentesis or thoracentesis with therapeutic intent, within 4 weeks of Screening. Subjects with planned therapeutic paracentesis or thoracentesis between Screening and Cycle 1 Day 1 dosing are excluded.
  • ✕ 4. Participant had systemic therapy or radiation therapy within 3 weeks prior to the first dose of study drug.
  • ✕ 5. Participants has known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is considered uncontrolled based on the criteria included in Appendix 2.
  • ✕ 6. Participant has a history of clinically meaningful coagulopathy, bleeding diathesis.
  • ✕ 7. Participant has cardiovascular disease, defined as:
  • ✕ 1. Uncontrolled hypertension defined as blood pressure \> 160/90 mmHg at Screening confirmed by repeat (medication permitted).

Where it's recruiting

Alabama

Mobile

Alaska

Anchorage

Arizona

Phoenix · Tucson

Arkansas

Little Rock

California

Duarte · La Jolla · Los Angeles · Newport Beach …

Colorado

Aurora

Connecticut

New Haven

Florida

Fort Myers · Miami Beach

Georgia

Atlanta · Gainesville

Illinois

Chicago · Urbana

Indiana

Indianapolis

Iowa

Iowa City

Source: ClinicalTrials.gov · NCT05548296 · last updated 2026-08-21